Specific Disorders Associated With NAFLD

Fatty Liver Disease: NASH and Related Disorders

Volumn , Issue , 2007, Pages 249-262

  Grant, Geraldine M ^a   Chandhoke, Vikas ^a   Younossi, Zobair M ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Cirrhosis; Diabetes; Insulin resistance; Nonalcoholic fatty liver disease (NAFLD); Pathogenic mechanisms

Indexed keywords

EID: 84882864226     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987438.ch21     Document Type: Chapter

References (115)

1. Younossi ZM, Diehl AM, Ong JP. Non-alcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002; 35: 746-52.
2. Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 2002; 17: 1136-43.
3. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
4. Lee RG. Non-alcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20: 594-8.
5. Powell EE, Cooksley WG, Hanson R et al. The natural history of non-alcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
6. Bacon BR, Farahvash MJ, Janney CG, Neuschwander- Tetri BA. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
7. Ratziu V, Bonyhay L, Di Martino V et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485-93.
8. Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002; 97: 2714-24.
9. Le Roith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001; 24: 588-97.
10. Muller MJ. [Hepatic complications in parenteral nutrition]. Z Gastroenterol 1996; 34: 36-40.
11. Nehra V, Angulo P, Buchman AL, Lindor KD. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci 2001; 46: 2347-52.
12. Saadeh S, Younossi ZM. The spectrum of non-alcoholic fatty liver disease: from steatosis to non-alcoholic steato- hepatitis. Cleve Clin J Med 2000; 67: 96-7, 101-4.
13. Fisher RL. Hepatobiliary abnormalities associated with total parenteral nutrition. Gastroenterol Clin North Am 1989; 18: 645-66.
14. Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in non-alcoholic fatty liver. Hepatology 2000; 32: 3-10.
15. Allard JP. Other disease associations with non-alcoholic fatty liver disease (NAFLD). Best Pract Res Clin Gastroenterol 2002; 16: 783-95.
16. Macsween R, Burt A. Liver pathology associated with diseases of other organs. In: Macsween R, Anthony P, Scheuer P, Burt A, BC P, eds. Pathology of Liver disease, 3rd edn. Churchill Livingstone, 1997: 713-64.
17. Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000; 132: 525-32.
18. Hall RI, Grant JP, Ross LH et al. Pathogenesis of hepatic steatosis in the parenterally fed rat. J Clin Invest 1984; 74: 1658-68.
19. Nussbaum MS, Fischer JE. Pathogenesis of hepatic steatosis during total parenteral nutrition. Surg Annu 1991; 23 (Part 2): 1-11.
20. Shaw AA, Hall SD, Franklin MR, Galinsky RE. The influence of L-glutamine on the depression of hepatic cytochrome P450 activity in male rats caused by total parenteral nutrition. Drug Metab Dispos 2002; 30: 177-82.
21. Denno R, Rounds JD, Faris R, Holejko LB, Wilmore DW. Glutamine-enriched total parenteral nutrition enhances plasma glutathione in the resting state. J Surg Res 1996; 61: 35-8.
22. Sandhu IS, Jarvis C, Everson GT. Total parenteral nutrition and cholestasis. Clin Liver Dis 1999; 3: 489-508, viii.
23. Nussbaum MS, Li S, Bower RH et al. Addition of lipid to total parenteral nutrition prevents hepatic steatosis in rats by lowering the portal venous insulin/glucagon ratio. J Parenter Enteral Nutr 1992; 16: 106-9.
24. Li S, Nussbaum MS, Teague D et al. Increasing dextrose concentrations in total parenteral nutrition (TPN) causes alterations in hepatic morphology and plasma levels of insulin and glucagon in rats. J Surg Res 1988; 44: 639-48.
25. Li SJ, Nussbaum MS, McFadden DW et al. Addition of glucagon to total parenteral nutrition (TPN) prevents hepatic steatosis in rats. Surgery 1988; 104: 350-7.
26. Li SJ, Nussbaum MS, McFadden DW, Dayal R, Fischer JE. Reversal of hepatic steatosis in rats by addition of glucagon to total parenteral nutrition (TPN). J Surg Res 1989; 46: 557-66.
27. Li SJ, Nussbaum MS, McFadden DW et al. Addition of L-glutamine to total parenteral nutrition and its effects on portal insulin and glucagon and the development of hepatic steatosis in rats. J Surg Res 1990; 48: 421-6.
28. Yeh SL, Chen WJ, Huang PC. Effects of L-glutamine on induced hepatosteatosis in rats receiving total parenteral nutrition. J Formos Med Assoc 1995; 94: 593-9.
29. Sokol RJ, Taylor SF, Devereaux MW et al. Hepatic oxidant injury and glutathione depletion during total parenteral nutrition in weanling rats. Am J Physiol 1996; 270: G691-700.
30. Dzakovic A, Kaviani A, Eshach-Adiv O et al. Trophic enteral nutrition increases hepatic glutathione and protects against peroxidative damage after exposure to endotoxin. J Pediatr Surg 2003; 38: 844-7.
31. Liang LJ, Yin XY, Luo SM et al. A study of the ameliorating effects of carnitine on hepatic steatosis induced by total parenteral nutrition in rats. World J Gastroenterol 1999; 5: 312-5.
32. Bowyer BA, Miles JM, Haymond MW, Fleming CR. L- carnitine therapy in home parenteral nutrition patients with abnormal liver tests and low plasma carnitine concentrations. Gastroenterology 1988; 94: 434-8.
33. Buchman AL, Dubin MD, Moukarzel AA et al. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology 1995; 22: 1399-403.
34. Hall RI, Ross LH, Bozovic MG, Grant JP. The effect of choline supplementation on hepatic steatosis in the parenterally fed rat. J Parenter Enteral Nutr 1985; 9: 597-9.
35. Gopalan S. Malnutrition: causes, consequences, and solutions. Nutrition 2000; 16: 556-8.
36. Jorquera F, Culebras JM, Gonzalez-Gallego J. Influence of nutrition on liver oxidative metabolism. Nutrition 1996; 12: 442-7.
37. Chitturi S, Farrell GC. Etiopathogenesis of non-alcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27-41.
38. Doherty JF, Adam EJ, Griffin GE, Golden MH. Ultra-sonographic assessment of the extent of hepatic steatosis in severe malnutrition. Arch Dis Child 1992; 67: 1348-52.
39. Agbedana EO, Johnson AO, Taylor GO. Studies on hepatic and extrahepatic lipoprotein lipases in protein- calorie malnutrition. Am J Clin Nutr 1979; 32: 292-8.
40. Vajreswari A, Narayanareddy K, Rao PS. Fatty acid composition of erythrocyte membrane lipid obtained from children suffering from kwashiorkor and marasmus. Metabolism 1990; 39: 779-82.
41. McLaren DS, Bitar JG, Nassar VH. Protein-calorie mal-nutrition and the liver. Prog Liver Dis 1972; 4: 527-36.
42. Sims EA, Horton ES. Endocrine and metabolic adaptation to obesity and starvation. Am J Clin Nutr 1968; 21: 1455-70.
43. Kim TS, Freake HC. High carbohydrate diet and starvation regulate lipogenic mRNA in rats in a tissue-specific manner. J Nutr 1996; 126: 611-7.
44. Iritani N, Nishimoto N, Katsurada A, Fukuda H. Regulation of hepatic lipogenic enzyme gene expression by diet quantity in rats fed a fat-free, high carbohydrate diet. J Nutr 1992; 122: 28-36.
45. Garg A. Lipodystrophies. Am J Med 2000; 108: 143-52.
46. Bhayana S, Hegele RA. The molecular basis of genetic lipodystrophies. Clin Biochem 2002; 35: 171-7.
47. Cauble MS, Gilroy R, Sorrell MF et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation 2001; 71: 892-5.
48. Garg A, Misra A. Hepatic steatosis, insulin resistance, and adipose tissue disorders. J Clin Endocrinol Metab 2002; 87: 3019-22.
49. Misra A, Garg A. Clinical features and metabolic derange-ments in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore) 2003; 82: 129-46.
50. Haque WA, Oral EA, Dietz K et al. Risk factors for diabetes in familial partial lipodystrophy, dunnigan variety. Diabetes Care 2003; 26: 1350-5.
51. Caux F, Dubosclard E, Lascols O et al. A new clinical condition linked to a novel mutation in lamins A and C with generalized lipoatrophy, insulin-resistant diabetes, disseminated leukomelanodermic papules, liver steatosis, and cardiomyopathy. J Clin Endocrinol Metab 2003; 88: 1006-13.
52. Herbst KL, Tannock LR, Deeb SS et al. Kobberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care 2003; 26: 1819-24.
53. Sbraccia P, D'Adamo M, Massimo F et al. Rosiglitazone treatment improves insulin sensitivity and increases pro-duction in lipodystrophic patients with mandibuloacral dysplasic. Diabetes 2003; 52.
54. Norman RJ. Obesity, polycystic ovary syndrome and anovulation: how are they interrelated? Curr Opin Obstet Gynecol 2001; 13: 323-7.
55. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000; 132: 989-93.
56. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001; 54: 447-53.
57. Davidson MB. Clinical implications of insulin resistance syndromes. Am J Med 1995; 99: 420-6.
58. Baumann E, Rosenfield R. Polycystic ovary syndrome in adolescence. Endocrinologist 2002; 12: 333-48.
59. Balen A, Michelmore K. What is polycystic ovary syndrome? Are national views important? Hum Reprod 2002; 17: 2219-27.
60. Achard C, Thiers J. Le virilisme pailaire et son association a l'insuffisance glycolytique (diabete des femmes a barb). Bull Acad Natl Med 1921; 86: 51-64.
61. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50: 113-6.
62. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002; 77: 1095-105.
63. Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003; 46: 325-40.
64. Robinson S, Henderson AD, Gelding SV et al. Dys- lipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf) 1996; 44: 277-84.
65. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
66. Wickenheisser J, Strauss J, McAllister J. Steroidogenic abnormalities in ovarian theca cells in polycystic ovary syndrome. Curr Opin Endocrinol Diabetes 2002; 9: 486-91.
67. Palsson R, Jonasson JG, Kristjansson M et al. Genotype- phenotype interactions in Wilson's disease: insight from an Icelandic mutation. Eur J Gastroenterol Hepatol 2001; 13: 433-6.
68. Pfeil SA, Lynn DJ. Wilson's disease: copper unfettered. J Clin Gastroenterol 1999; 29: 22-31.
69. Gu M, Cooper JM, Butler P et al. Oxidative- phosphorylation defects in liver of patients with Wilson's disease. Lancet 2000; 356: 469-74.
70. Mansouri A, Gaou I, Fromenty B et al. Premature oxidative aging of hepatic mitochondrial DNA in Wilson's disease. Gastroenterology 1997; 113: 599-605.
71. Shah SS, Desai HG. Fatty liver and elevated transaminases with heterozygous apolipoprotein B deficiency. J Assoc Physicians India 2001; 49: 284-5.
72. Tarugi P, Lonardo A, Ballarini G et al. A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5). J Hepatol 2000; 33: 361-70.
73. Black DD, Hay RV, Rohwer-Nutter PL et al. Intestinal and hepatic apolipoprotein B gene expression in abetalipoproteinemia. Gastroenterology 1991; 101: 520-8.
74. Triantafillidis JK, Kottaras G, Sgourous S et al. A-β- lipoproteinemia:clinical and laboratory features,therapeutic manipulations, and follow-up study of three members of a Greek family. J Clin Gastroenterol 1998; 26: 207-11.
75. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in non-alcoholic steato- hepatitis. Hepatology 2002; 35: 898-904.
76. Lin MC, Gordon D, Wetterau JR. Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res 1995; 36: 1073-81.
77. Rader DJ, Brewer HB Jr. Abetalipoproteinemia: new insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. J Am Med Assoc 1993; 270: 865-9.
78. Avigan MI, Ishak KG, Gregg RE, Hoofnagle JH. Morphologic features of the liver in abetalipoproteinemia. Hepatology 1984; 4: 1223-6.
79. Grieco A, Miele L, Pignatoro G et al. Is coeliac disease a confounding factor in the diagnosis of NASH? Gut 2001; 49: 596.
80. Bottaro G, Cataldo F, Rotolo N, Spina M, Corazza GR. The clinical pattern of subclinical/silent celiac disease: an analysis on 1026 consecutive cases. Am J Gastroenterol 1999; 94: 691-6.
81. Riestra S, Dominguez F, Rodrigo L. Nodular regenerative hyperplasia of the liver in a patient with celiac disease. J Clin Gastroenterol 2001; 33: 323-6.
82. Franzese A, Iannucci MP, Valerio G et al. Atypical celiac disease presenting as obesity-related liver dysfunction. J Pediatr Gastroenterol Nutr 2001; 33: 329-32.
83. Shamir R, Koren I, Rosenbach Y et al. Celiac, fatty liver, and pancreatic insufficiency. J Pediatr Gastroenterol Nutr 2001; 32: 490-2.
84. Capron JP, Sevenet F, Quenum C et al. [Massive hepatic steatosis disclosing adult coeliac disease: study of a case and review of the literature]. Gastroenterol Clin Biol 1983; 7: 256-60.
85. Christl SU, Muller JG. [Fatty liver in adult coeliac disease]. Dtsch Med Wochenschr 1999; 124: 691-4.
86. Davison S. Coeliac disease and liver dysfunction. Arch Dis Child 2002; 87: 293-6.
87. Gonzalez-Abraldes J, Sanchez-Fueyo A, Bessa X et al. Persistent hypertransaminasemia as the presenting feature of celiac disease. Am J Gastroenterol 1999; 94: 1095-7.
88. Angulo P. Non-alcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
89. Novacek G, Miehsler W, Wrba F et al. Prevalence and clinical importance of hypertransaminasaemia in coeliac disease. Eur J Gastroenterol Hepatol 1999; 11: 283-8.
90. Morillas MJ, Gaspar E, Moles JR et al. [Adult coeliac disease and hepatopathy]. Rev Esp Enferm Dig 1991; 79: 197-200.
91. Mitchison HC, Record CO, Bateson MC, Cobden I. Hepatic abnormalities in coeliac disease: three cases of delayed diagnosis. Postgrad Med J 1989; 65: 920-2.
92. Naschitz JE, Yeshurun D, Zuckerman E, Arad E, Boss JH. Massive hepatic steatosis complicating adult celiac disease: report of a case and review of the literature. Am J Gastroenterol 1987; 82: 1186-9.
93. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002; 17 (Suppl.): S186-90.
94. Marignani M, Angeletti S. Non-alcoholic fatty liver disease. N Engl J Med 2002; 347: 768-9; author reply 768-9.
95. Robertson G, Leclercq I, Farrell GC. Non-alcoholic steatosis and steatohepatitis. II. Cytochrome P450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1135-9.
96. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002; 22: 185-94.
97. Novak D, Lewis J. Drug-induced liver disease. Curr Opin Gastroenterol 2003; 19: 203-15.
98. Lewis J. Drug-induced liver disease. Curr Opin Gastro-enterol 2002; 18: 307-13.
99. Stravitz RT, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis 2003; 7: 435-51.
100. Cai Q, Bensen M, Greene R, Kirchner J. Tamoxifen- induced transient multifocal hepatic fatty infiltration. Am J Gastroenterol 2000; 95: 277-9.
101. Coskun U, Toruner FB, Gunel N. Tamoxifen therapy and hepatic steatosis. Neoplasma 2002; 49: 61-4.
102. Hamada N, Ogawa Y, Saibara T et al. Toremifene- induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. Int J Oncol 2000; 17: 1119-23.
103. Tuquet C, Dupont J, Mesneau A, Roussaux J. Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria. Cell Biol Toxicol 2000; 16: 207-19.
104. Steindl P, Ferenci P, Dienes HP et al. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997; 113: 212-8.
105. Saibara T, Onishi S. [Non-alcoholic steatohepatitis(NASH)]. Nippon Shokakibyo Gakkai Zasshi 2002; 99: 570-6.
106. Chariot P, Drogou I, de Lacroix-Szmania I et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999; 30: 156-60.
107. Brivet FG, Nion I, Megarbane B et al. Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment: a respiratory chain dysfunction? J Hepatol 2000; 32: 364-5.
108. Yki-Jarvinen H, Sutinen J, Silveira A et al. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol 2003; 23: 688-94.
109. Nolan D, Hammond EAM, Taylor L et al. Mitochondrial DNA depletion and morphologic changes inadipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17: 1329-38.
110. Vigouroux C, Maachi M, Nguyen TH et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003; 17: 1503-11.
111. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-5.
112. Simon C, Schlienger JL, Cherfan J et al. [Efficacy of dexamethasone in the treatment of hyperthyroidism caused by amiodarone]. Presse Med 1984; 13: 2767.
113. Pessayre D, Mansouri A, Fromenty B. Non-alcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2002; 282: G193-9.
114. Dourakis SP, Sevastianos VA, Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol 2002; 97: 1074-5.
115. Nanki T, Koike R, Miyasaka N. Subacute severe steato-hepatitis during prednisolone therapy for systemic lupus erythematosis. Am J Gastroenterol 1999; 94: 3379.